Cymabay醫療 CBAY 深 滬
等待開盤 10-31 09:30:00 美东时间
32.48
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 32.48
- 總市值 37.35亿
- 52周最高 32.50
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 7.2609
- 委 比 0.00%
- 總股本 1.15亿
- 歷史最高 32.50
- 量 比 0
- 振 幅 0.00%
- 歷史最低 0.82
- 每 手 1
- 風險率 5.87%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Gilead's Aggressive Push Beyond HIV Treatments - Plans To Increase Cancer-Focused CAR-T Treatment Production
Gilead Sciences plans to quadruple cell therapy cancer treatment production by 2026. With a focus on CAR-T treatments like Yescarta and Tecartus, Gilead aims to diversify into oncology. Anticipating a third of revenue from oncology by decade's end.
2024-03-16 00:51
Top 3 Health Care Stocks That Are Ticking Portfolio Bombs
As of March 14, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
2024-03-14 20:57
INVESTIGATION ALERT: Halper Sadeh LLC Investigates FANG, WISH, CBAY
NEW YORK, Feb. 12, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or...
2024-02-13 01:30
William Blair Downgrades CymaBay Therapeutics to Market Perform
William Blair analyst Andy Hsieh downgrades CymaBay Therapeutics (NASDAQ:CBAY) from Outperform to Market Perform.
2024-02-13 00:44
Drugmaker Gilead Sciences Scoops Up Liver-Disease Focused CymaBay Therapeutics For $4.3B
Gilead Sciences will acquire CymaBay Therapeutics for $4.3 billion, advancing liver disease treatment with seladelpar. FDA priority review was granted, and there is potential for significant revenue growth.
2024-02-12 22:22
CymaBay Announces FDA Accepted NDA For Seladelpar For Primary Biliary Cholangitis; FDA Grants Priority Review
- FDA has granted Priority Review with a target PDUFA date of August 14 -
2024-02-12 21:47
6 Analysts Have This to Say About CymaBay Therapeutics
Analysts have provided the following ratings for CymaBay Therapeutics (NASDAQ:C...
2023-12-16 04:00
CymaBay Therapeutics Q3 EPS $(0.32) Misses $(0.30) Estimate
CymaBay Therapeutics (NASDAQ:CBAY) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.30) by 6.67 percent. This is a 14.29 percent decrease over losses of $(0.28) per share
2023-11-08 05:13
Earnings Outlook For CymaBay Therapeutics
CymaBay Therapeutics (NASDAQ:CBAY) is set to give its latest quarterly earnings...
2023-11-07 05:01
Investors Eye CymaBay's AFFIRM Study As Regulatory Uncertainties Ease
Thursday, CymaBay Therapeutics Inc (NASDAQ: CBAY) initiated the AFFIRM Phase 3b/4 confirmatory study to evaluate the effect of seladelpar on clinical outcomes in patients with compensated cirrhosis due to
2023-09-22 04:06
